ReviewHaematologica2015
Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).
Review in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.Haematologica · 2017Guideline
- Extranodal Lymphoplasmacytic Lymphoma Responding Rapidly to Zanubrutinib: A Case Series.Clinical case reports · 2026Article
- Zanubrutinib Combined With Rituximab in the Treatment of Bing-Neel Syndrome: A Case Report.Clinical case reports · 2025Article
- Bing-Neel Syndrome in Waldenström Macroglobulinemia: Updates on Clinical Management and BTK Inhibitor Efficacy.Cancers · 2025Review
- The Impact of Tirabrutinib Monotherapy for the Treatment of Bing-Neel Syndrome: A Multicenter Retrospective Study.American journal of hematology · 2025Article
- Cutaneous macroglobulinosis with Waldenström macroglobulinemia and Bing-Neel syndrome: A case report.JAAD case reports · 2025Article
- Article
- Central nervous system involvement in Waldenström macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation.Annals of hematology · 2025Article
- Bing-Neel Syndrome: A Missed Opportunity.Cureus · 2025Article
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy.Mediterranean journal of hematology and infectious diseases · 2025Review
- Extramedullary disease in Waldenström macroglobulinemia: A population-based observational study.EJHaem · 2024Article
- MYD88 mutation-positive indolent B-cell lymphoma with CNS involvement: Bing-Neel syndrome mimickers.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Ibrutinib as treatment for Bing-Neel syndrome reclassified as glioblastoma: a case report.Journal of medical case reports · 2024Article
- Article
- Bing-Neel syndrome, a rare manifestation of WM; a case report and review of literature.Clinical case reports · 2024Article
- Bing Neel syndrome presenting as isolated cranial nerve palsies - a case report.eNeurologicalSci · 2024Article
- Waldenstrom Macroglobulinemia Recurrence with Bing-Neel Syndrome Presentation.Reports (MDPI) · 2024Article
- Bing-Neel syndrome: a rare neurological complication of Waldenström macroglobulinaemia.BMJ case reports · 2024Article
- Pathophysiology and Treatments of Complications of Waldenström's Macroglobulinemia.Clinical hematology international · 2024Article
- Bing-Neel Syndrome: An Unknown GCA Mimicker.Case reports in rheumatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 17 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system involvement by malignant cells is a rare complication of Waldenström macroglobulinemia, and this clinicopathological entity is referred to as the Bing-Neel syndrome. There is currently no consensus on the diagnostic criteria, therapeutic approaches and response evaluation for this syndrome. In this series, we retrospectively analyzed 44 French patients with Bing-Neel syndrome. Bing-Neel syndrome was the first manifestation of Waldenström macroglobulinemia in 36% of patients. When Waldenström macroglobulinemia was diagnosed prior to Bing-Neel syndrome, the median time interval between this diagnosis and the onset of Bing-Neel syndrome was 8.9 years. This study highlights the possibility of the occurrence of Bing-Neel syndrome without any other evidence of progression of Waldenström macroglobulinemia. The clinical presentation was heterogeneous without any specific signs or symptoms. Biologically, the median lymphocyte count in the cerebrospinal fluid was 31/mm(3). Magnetic resonance imaging revealed abnormalities in 78% of the cases. The overall response rate after first-line treatment was 70%, and the overall survival rate after the diagnosis of Bing-Neel syndrome was 71% at 5 years. Altogether, these results suggest that Bing-Neel syndrome should be considered in the context of any unexplained neurological symptoms associated with Waldenström macroglobulinemia. The diagnostic approach should be based on cerebrospinal fluid analysis and magnetic resonance imaging of the brain and spinal axis. It still remains difficult to establish treatment recommendations or prognostic factors in the absence of large-scale, prospective, observational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.